462 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 24 month survival data

• Magnus Jaderberg,
• Victor Levitsky,
• Luis Paz-Ares,
• Lukasz Kuryk,
• Nicolas Isambert,
• Susana Cedres,
• Charles Ricordel,
• Santiago Ponce Aix,
• Anne-Sophie Moller,
• Sylvia Vetrhus

Affiliations

Magnus Jaderberg

1Research and Development, Oslo, Norway

Victor Levitsky

1Research and Development, Oslo, Norway

Luis Paz-Ares

H12O-CNIO Lung Cancer Clinical Research Unit, Health Research Institute Hospital 12 de Octubre (imas12) / Spanish National Cancer Research Center (CNIO), Madrid, Spain

Lukasz Kuryk

1Research and Development, Oslo, Norway

Nicolas Isambert

2Medical Oncology, Sevilla, Spain

Susana Cedres

2Medical Oncology, Sevilla, Spain

Charles Ricordel

Department of Respiratory Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France

Santiago Ponce Aix

2Medical Oncology, Sevilla, Spain

Anne-Sophie Moller

1Research and Development, Oslo, Norway

Sylvia Vetrhus

1Research and Development, Oslo, Norway